AR123532A1 - CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND USES - Google Patents

CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND USES

Info

Publication number
AR123532A1
AR123532A1 ARP210102579A ARP210102579A AR123532A1 AR 123532 A1 AR123532 A1 AR 123532A1 AR P210102579 A ARP210102579 A AR P210102579A AR P210102579 A ARP210102579 A AR P210102579A AR 123532 A1 AR123532 A1 AR 123532A1
Authority
AR
Argentina
Prior art keywords
coronavirus
domain
vaccine
amino acid
acid sequence
Prior art date
Application number
ARP210102579A
Other languages
Spanish (es)
Inventor
Hidalgo Tommy Idrovo
Lorena Itati Ibaez
Natalia Brenda Fernandez
Javier Santos
Cecilia Dalessio
Alejandro Daniel Nadra
Florencia Pignataro
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Univ De Buenos Aires Uba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Univ De Buenos Aires Uba filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Priority to ARP210102579A priority Critical patent/AR123532A1/en
Priority to PCT/US2022/043578 priority patent/WO2023043868A2/en
Publication of AR123532A1 publication Critical patent/AR123532A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Vacuna y obtención de anticuerpos contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos. La vacuna contra un coronavirus que comprende el dominio RBD de la proteína espiga de coronavirus deglicosilado y adyuvantes, en donde el dominio RDB es producido en P. pastoris. Entre otras, la secuencia de aminoácidos del dominio RBD puede ser la secuencia SEQ ID Nº 1 o SEQ ID Nº 2, en donde la vacuna puede comprender además uno o varios adyuvantes. Reivindicación 10: Una cepa de levadura transformada, caracterizada porque expresa y libera al medio una proteína que comprende la secuencia de aminoácidos del dominio RBD de la proteína espiga de SARS-CoV-2 unida a una secuencia de aminoácidos de reconocimiento de Sortasa A unida a una etiqueta His6, en donde la expresión es estable. Reivindicación 13: Un método de detección de anticuerpos anti coronavirus, caracterizado porque comprende al menos las siguientes etapas: a. contactar el dominio RBD deglicosilado de la proteína espiga de un coronavirus con una cantidad de una muestra biológica, en donde el dominio RBD es producido en P. pastoris; y b. incubar y revelar.Vaccine and obtaining antibodies against coronaviruses, yeast strains, detection methods, treatment methods and uses. The vaccine against a coronavirus comprising the RBD domain of the deglycosylated coronavirus spike protein and adjuvants, wherein the RDB domain is produced in P. pastoris. Among others, the amino acid sequence of the RBD domain can be the sequence SEQ ID No. 1 or SEQ ID No. 2, where the vaccine can also comprise one or more adjuvants. Claim 10: A transformed yeast strain, characterized in that it expresses and releases into the medium a protein comprising the amino acid sequence of the RBD domain of the SARS-CoV-2 spike protein linked to a Sortase A recognition amino acid sequence linked to a His6 tag, where the expression is stable. Claim 13: A method for detecting anti-coronavirus antibodies, characterized in that it comprises at least the following steps: a. contacting the deglycosylated RBD domain of a coronavirus spike protein with a quantity of a biological sample, wherein the RBD domain is produced in P. pastoris; and b. incubate and reveal.

ARP210102579A 2021-09-16 2021-09-16 CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND USES AR123532A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ARP210102579A AR123532A1 (en) 2021-09-16 2021-09-16 CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND USES
PCT/US2022/043578 WO2023043868A2 (en) 2021-09-16 2022-09-15 Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP210102579A AR123532A1 (en) 2021-09-16 2021-09-16 CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND USES

Publications (1)

Publication Number Publication Date
AR123532A1 true AR123532A1 (en) 2022-12-14

Family

ID=84578120

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102579A AR123532A1 (en) 2021-09-16 2021-09-16 CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND USES

Country Status (2)

Country Link
AR (1) AR123532A1 (en)
WO (1) WO2023043868A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
US11690907B2 (en) * 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US20210206810A1 (en) * 2019-11-20 2021-07-08 Ingenza Ltd. Detection of Optimal Recombinants Using Fluorescent Protein Fusions
CN112300251B (en) * 2020-02-24 2022-04-05 成都威斯克生物医药有限公司 Protein and vaccine for anti SARS-CoV-2 infection
US11376320B2 (en) * 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
RU2720614C9 (en) * 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Immunobiological agent and a method for use thereof for inducing specific immunity against the sars-cov-2 severe acute respiratory syndrome virus (versions)
CN111920946B (en) * 2020-08-07 2021-05-28 合肥诺为尔基因科技服务有限公司 Cyclic dinucleotide modified aluminum nanoparticle vaccine adjuvant-delivery system and SARS-CoV-2 subunit vaccine based on the same

Also Published As

Publication number Publication date
WO2023043868A3 (en) 2023-10-12
WO2023043868A2 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Li et al. Protozoa: amebiasis
Naglik et al. Candida albicans proteinases and host/pathogen interactions
Bechah et al. Identification of rickettsial infections by using cutaneous swab specimens and PCR
Dąbrowska et al. The use of a one-step PCR method for the identification of Microsporum canis and Trichophyton mentagrophytes infection of pets.
Sunarto et al. Characteristics of cyprinid herpesvirus 3 in different phases of infection: implications for disease transmission and control
Flockhart et al. Enzyme polymorphism in Trichinella
AR123532A1 (en) CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND USES
Maraghi et al. Identification of cutaneous leishmaniasis agents by nested Po-Lymerase chain reaction (Nested-PCR) in Shush City, Khuzestan Province, Iran
Selseleh et al. Brain tissue cysts in infected mice with RH-strain of Toxoplasma gondii and evaluation of BAG1 and SAG1 genes expression
Yamaji et al. A salivary cystatin, HlSC-1, from the ixodid tick Haemaphysalis longicornis play roles in the blood-feeding processes
Ebrahimi et al. Molecular characterization of Theileria equi infection in horse populations belonging to West Azerbaijan, Iran: insights into the importance of Equine Merozoite Antigen (EMA)-1 in its diagnosis
CN105296479A (en) Specific primers for identifying mulberry tree bacterial wilt, and applications thereof
Li et al. Molecular investigation of piroplasma infection in white yaks (Bos grunniens) in Gansu province, China
Zollfrank et al. Fluorescence immunohistochemical detection of Armillaria and Heterobasidion in Norway spruce
Sarvi et al. Molecular cloning and expression of EG95 gene of Iranian isolates of Echinococcus granulosus
Okeke et al. Reverse transcription-3′ rapid amplification of cDNA ends-nested PCR of ACT1 and SAP2 mRNA as a means of detecting viable Candida albicans in an in vitro cutaneous candidiasis model
Sufiate et al. Nematicidal activity of proteases from Euphorbia milii
Ralte et al. Detection of Toxoplasma gondii targeting the repetitive microsatellite sequence by PCR.
Bonants et al. Characterization and detection of Phytophthora fragariae in plant, water and soil by molecular methods
Karthikeyan et al. Development and comparison of ELISA and PCR methods for the early detection of Ganoderma disease of coconut
CN100510079C (en) Malignant malarial parasite dynein gene
Eftekhar et al. Seroprevalence of Acanthamoeba antibodies in rheumatoid arthritis patients by IFAT, Tehran, Iran 2007
Vather Vivapain: a cysteine peptidase from Trypanosoma vivax.
Johar Hussian et al. An Improved Heamagglutination Inhibition Test for Rapid Diagnosis and Stereotyping of Avian Infectious Bronchitis Virus
Cervantes-Sandoval et al. Characterization of Naegleria fowleri strains isolated from human cases of primary amoebic meningoencephalitis in Mexico